CM
KRYS icon

Caption Management’s Krystal Biotech KRYS Stock Holding History

Caption Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.17M Hold
20,000
– – 0.03% 524
2025
Q4 		$4.93M Buy
20,000
+15,000
+300% +$3.16M 0.03% 524
2025
Q3 		$883K Sell
5,000
-15,000
-75% -$2.25M 0.01% 1144
2025
Q2 		$2.75M Hold
20,000
– – 0.03% 619
2025
Q1 		$3.61M Sell
20,000
-24,700
-55% -$4.15M 0.03% 499
2024
Q4 		$7M Buy
44,700
+24,700
+124% +$4.38M 0.07% 275
2024
Q3 		$3.64M Hold
20,000
– – 0.06% 377
2024
Q2 		$3.67M Buy
20,000
+3,000
+18% +$504K 0.06% 340
2024
Q1 		$3.02M Sell
17,000
-23,000
-58% -$3.19M 0.05% 428
2023
Q4 		$4.96M Sell
40,000
-2,700
-6% -$299K 0.07% 342
2023
Q3 		$4.95M Buy
42,700
+22,700
+114% +$2.77M 0.08% 319
2023
Q2 		$2.35M Buy
+20,000
New +$2.04M 0.04% 456
2022
Q1 		– Sell
-41,200
Closed -$2.88M – 1719
2021
Q4 		$2.88M Buy
+41,200
New +$2.4M 0.03% 654

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's KRYS Position: Q1 2025 in Review

Caption Management sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 22,339 shares — an estimated $3.76M sold.

Caption Management first reported a position in KRYS in Q4 2021 and held it in 3 quarters. The position peaked at $3.5M in Q4 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Caption Management reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 22,339 Krystal Biotech shares in Q1 2025, an estimated $3.76M.
  • Caption Management first reported a position in Krystal Biotech in Q4 2021 and held it in 3 quarters.
  • Caption Management's Krystal Biotech position peaked at $3.5M in Q4 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.